Cytochrome P-450 3A4: Regulation and role in drug metabolism

被引:1018
作者
Guengrich, FP [1 ]
机构
[1] Vanderbilt Univ, Dept Biochem, Sch Med, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Ctr Mol Toxicol, Sch Med, Nashville, TN 37232 USA
关键词
nifedipine oxidation; cooperativity; genetic polymorphism; P-170; glycoprotein; heterologous expression;
D O I
10.1146/annurev.pharmtox.39.1.1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cytochrome P-450 (P-450) 3A4 is the most abundant P-450 expressed in human liver and small intestine. P-450 3A4 contributes to the metabolism of approximately half the drugs in use today, and variations in its catalytic activity are important in issues of bioavailability and drug-drug interactions. The gene is known to be inducible by barbiturates, glucocorticoids, and rifampicin in humans and in isolated hepatocytes, although the mechanism remains unclear. The 5'-untranslated region includes putative basal transcription element, hepatocyte nuclear factor, p53, AP-3, glucocorticoid regulatory element, pregnane X receptor, and estrogen receptor element sequences. Recently, the GRE element has been shown to act in a classic glucocorticoid response. Several issues remain to be resolved regarding the catalytic activity of the P-450 3A4 protein, including rate-limiting steps and the need for cytochrome b(5), divalent cations, and acidic phospholipid systems for optimal activity. Another issue involves the basis of the homotropic and heterotropic cooperativity seen with the enzyme. The in vivo significance of these findings remains to be further established. In addition to more basic studies on P-450 3A4, several areas of practical interest to the pharmaceutical industry require development.
引用
收藏
页码:1 / 17
页数:17
相关论文
共 108 条
  • [1] ETHNIC-DIFFERENCES IN THE PHARMACOKINETICS OF ORAL NIFEDIPINE
    AHSAN, CH
    RENWICK, AG
    MACKLIN, B
    CHALLENOR, VF
    WALLER, DG
    GEORGE, CF
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 31 (04) : 399 - 403
  • [2] AOYAMA T, 1989, J BIOL CHEM, V264, P10388
  • [3] MULTIDRUG RESISTANCE GENES, P-GLYCOPROTEIN AND THE LIVER
    ARIAS, IM
    [J]. HEPATOLOGY, 1990, 12 (01) : 159 - 165
  • [4] KETOCONAZOLE AND SULFAPHENAZOLE AS THE RESPECTIVE SELECTIVE INHIBITORS OF P4503A AND 2C9
    BALDWIN, SJ
    BLOOMER, JC
    SMITH, GJ
    AYRTON, AD
    CLARKE, SE
    CHENERY, RJ
    [J]. XENOBIOTICA, 1995, 25 (03) : 261 - 270
  • [5] Barwick JL, 1996, MOL PHARMACOL, V50, P10
  • [6] ISOLATION AND SEQUENCE DETERMINATION OF A CDNA CLONE RELATED TO HUMAN CYTOCHROME-P-450 NIFEDIPINE OXIDASE
    BEAUNE, PH
    UMBENHAUER, DR
    BORK, RW
    LLOYD, RS
    GUENGERICH, FP
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (21) : 8064 - 8068
  • [7] BEAUNE PH, 1986, DRUG METAB DISPOS, V14, P437
  • [8] Oxidation kinetics of ethanol by human cytochrome P450 2E1 - Rate-limiting product release accounts for effects of isotopic hydrogen substitution and cytochrome b(5) on steady-state kinetics
    Bell, LC
    Guengerich, FP
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (47) : 29643 - 29651
  • [9] P-glycoproteins and multidrug resistance
    Bellamy, WT
    [J]. ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1996, 36 : 161 - 183
  • [10] Coexpression of a human P450 (CYP3A4) and P450 reductase generates a highly functional monooxygenase system in Escherichia coli
    Blake, JAR
    Pritchard, M
    Ding, SH
    Smith, GCM
    Burchell, B
    Wolf, CR
    Friedberg, T
    [J]. FEBS LETTERS, 1996, 397 (2-3) : 210 - 214